Overview

Safety and Efficacy of Changing to DuoTrav From Prior Therapy

Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study to assess the safety and efficacy of changing to DuoTrav® from prior bimatoprost 0.03%/timolol 0.5% (used concomitantly or in a fixed combination) pharmacotherapy in uncontrolled patients with open-angle glaucoma or ocular hypertension.
Phase:
Phase 4
Details
Lead Sponsor:
Alcon Research
Treatments:
Cloprostenol
Ophthalmic Solutions
Timolol
Travoprost